<DOC>
	<DOC>NCT01953055</DOC>
	<brief_summary>Current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy. Evidence has emerged that prostate cancer has a low α/β ratio in the range of 1-3 Gy. Even with high risk tumors, prostate cancer is hypothesized to have a greater sensitivity to large fraction sizes and high dose per fraction radiotherapy theoretically allows for biological dose escalation with fewer visits and no additional toxicity. Therefore, we hope to determine the toxicity, quality of life, biochemical and pathological control of SBRT for high risk prostate cancer incorporating ENI.</brief_summary>
	<brief_title>SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>informed consent obtained men &gt; 18 years of age histologically confirmed prostate adenocarcinoma (centrally reviewed) high risk prostate cancer, defined as at least one of clinical stage T3 or Gleason 810, or PSA &gt; 20ng/mL prior pelvic radiotherapy anticoagulation medication (if unsafe to discontinue for gold seed insertion) diagnosis of bleeding diathesis large prostate (&gt;90cm3) on imaging at time of gold seed insertion no evidence of castrate resistance (defined as PSA &lt; 3ng/mL while testosterone is &lt; 0.7nmol/L definitive regional or distant metastatic disease on staging investigations</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stereotactic ablative radiotherapy</keyword>
	<keyword>androgen deprivation therapy</keyword>
</DOC>